- Home
- CET vs PSNL Comparison
CET vs PSNL Comparison
Compare CET & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CET | PSNL |
|---|---|---|
| Founded | 1929 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CET | PSNL |
|---|---|---|
| Price | $54.40 | $16.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 28.8K | ★ 3.5M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | N/A | $15.34 |
| Revenue Next Year | N/A | $41.46 |
| P/E Ratio | $6.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $47.82 | $4.73 |
| 52 Week High | $55.99 | $18.89 |
Technical Indicators
Market Signals| Indicator | CET | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 62.47 |
| Support Level | N/A | $7.41 |
| Resistance Level | N/A | $18.89 |
| Average True Range (ATR) | 0.00 | 0.80 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 63.05 |
Price Performance
Historical ComparisonAbout CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. The company's investment objective is long-term growth of capital. It invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.